Nasdaq Determined To Delist Avalo Therapeutics' Securities From Nasdaq, Unless Co's Timely Requests Appeal Of Determination To Hearings Panel
Portfolio Pulse from Benzinga Newsdesk
Nasdaq has decided to delist Avalo Therapeutics' securities unless the company timely requests an appeal of the determination to a hearings panel.
September 13, 2023 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Avalo Therapeutics' securities are at risk of being delisted from Nasdaq unless the company appeals the decision in a timely manner.
The news of a potential delisting from Nasdaq is a significant negative event for any company. It can lead to a decrease in the company's stock price due to the potential loss of liquidity and visibility. Therefore, this news is highly relevant and important for Avalo Therapeutics and its investors.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100